Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4355006 | 0.94 | CA1 (0.46) | EPHX2TSHRKMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL4439325 | 0.92 | CA1 (0.50) | EPHX2TSHRKMT2AL3MBTL1CA1 | |
| SCHEMBL3503020 | 0.92 | CA1 (0.50) | EPHX2TSHRKMT2AL3MBTL1CA1 | |
| SCHEMBL625139 | 0.92 | EPHX2 (0.44) | EPHX2TSHRKMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL13013229 | 0.86 | EPHX2 (0.48) | EPHX2TSHRKMT2AL3MBTL1CA1 | |
| SCHEMBL31043981 | 0.83 | CA1 (0.48) | EPHX2TSHRKMT2AL3MBTL1CA1 | |
| SCHEMBL21670596 | 0.83 | EPHX2 (0.52) | EPHX2TSHRKMT2AL3MBTL1CA1 | |
| SCHEMBL5289842 | 0.83 | EPHX2 (0.52) | EPHX2TSHRKMT2AL3MBTL1CA1 | |
| SCHEMBL25355555 | 0.83 | EPHX2 (0.43) | EPHX2TSHRKMT2AL3MBTL1CA1 | |
| SCHEMBL20624943 | 0.82 | TSHR (0.49) | EPHX2TSHRSMN1; SMN2L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215009-A1 | PROCESS FOR MAKING CRYSTALLINE 2-(3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-1-(CYCLOPROPYLSULFONYL)AZETIDIN-3-YL)ACETONITRILE | ELANCO US INC. | 2025-07-03 | — | — | US | disclosed |
| US-12234239-B2 | Crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile | ELANCO US INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20230404925-A1 | JAK INHIBITORS HAVING A SPECIFIC PARTICLE SIZE DISTRIBUTION | ELANCO US INC. | 2023-12-21 | — | — | US | disclosed |
| US-20230056365-A1 | PROCESS FOR MAKING CRYSTALLINE 2-(3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-1-(CYCLOPROPYLSULFONYL)AZETIDIN-3-YL)ACETONITRILE | ELANCO US INC. | 2023-02-23 | — | — | US | disclosed |
| US-11548895-B2 | Process for making crystalline 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile | ELANCO US INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2017088738-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | 南京明德新药研发股份有限公司 | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234239-B2 | Crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile | PRNP, TTR, SFPQ | EPHX2 4402/4885TSHR 4015/4885KMT2A 4411/4885 |
| US-20250215009-A1 | PROCESS FOR MAKING CRYSTALLINE 2-(3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-1-(CYCLOPROPYLSULFONYL)AZETIDIN-3-YL)ACETONITRILE | PRNP, TTR, SFPQ | EPHX2 4329/4885TSHR 4386/4885KMT2A 4175/4885 |
| US-20230056365-A1 | PROCESS FOR MAKING CRYSTALLINE 2-(3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-1-(CYCLOPROPYLSULFONYL)AZETIDIN-3-YL)ACETONITRILE | PRNP, TTR, SFPQ | EPHX2 4329/4885TSHR 4386/4885KMT2A 4175/4885 |
| US-20230404925-A1 | JAK INHIBITORS HAVING A SPECIFIC PARTICLE SIZE DISTRIBUTION | JAK1, JAK3, JAK2 | EPHX2 4574/4885TSHR 2076/4885KMT2A 1176/4885 |
| US-11548895-B2 | Process for making crystalline 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile | PRNP, TTR, SFPQ | EPHX2 4329/4885TSHR 4386/4885KMT2A 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.